⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 17, 2024Pediatric PulmonologyOpen Access

Dupilumab 200 mg was efficacious in children (6–11 years) with moderate‐to‐severe asthma for up to 2 years: EXCURSION open‐label extension study

Wanda Phipatanakul Christian Vogelberg Leonard B. Bacharier Sharon Dell Arman Altincatal Rebecca Gall Oliver Ledanois Harry Sacks Juby A. Jacob‐Nara Yamo Deniz Paul J. Rowe

View Full Paper

Ask AI

Bookmark

Share

Abstract

The phase 3 VOYAGE (NCT02948959) and open-label extension EXCURSION (NCT03560466) studies evaluated dupilumab in children (6-11 years) with uncontrolled moderate-to-severe asthma. This post hoc analysis assessed the efficacy and safety of add-on dupilumab 200 mg every 2 weeks (q2w), the largest dose cohort in both studies, in children from VOYAGE who participated in EXCURSION.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Phipatanakul et al. (2024) studied this question.

synapsesocial.com/papers/68e60005b6db6435875935f8 https://doi.org/10.1002/ppul.27167

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)2024 · 17 citations
2Long-term dupilumab effect on lung function in paediatric patients with uncontrolled asthma2024
3Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic DermatitisHuman Clinical Trial · 2023 · 43 citations
4OP-059 Lung function improvement by dupilumab associated with better asthma control in children2024
5Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthmaLate-Phase Clinical Trial · 2020 · 54 citations

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)2022
Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase <scp>II</scp> a open‐label trial and subsequent phase <scp>III</scp> open‐label extension2019
Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study2024
Postoperative Respiratory Events and Risk Factors After Hip Reconstruction in Children With Neurological Complex Chronic ConditionsPediatric Pulmonology · 2026
Test‐Retest Reliability, Learning Effect and Measurement Error of the Modified Shuttle Test (MST) in Children With Asthma: A Multicenter StudyPediatric Pulmonology · 2026

More from Pediatric Pulmonology

More from Harvard University